ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,926, issued on Nov. 25, was assigned to DAIICHI SANKYO Co. LTD. (Tokyo).
"Anti-MUC1 antibody-drug conjugate" was invented by Johanna Gellert (Berlin), Anke Flechner (Berlin), Doreen Weigelt (Berlin), Antje Danielczyk (Berlin) and Akiko Nagase (Tokyo).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies."
The patent was filed on M...